Nanolek has opened the first stage of the biopharmaceutical complex

Opening of a new domestic production of medicines
it took place in the Kirov region

Press Service of the Plenipotentiary Representative of the President of the Russian Federation in the Volga Federal District

On December 23, 2014, Mikhail Babich, Plenipotentiary Representative of the President of the Russian Federation in the Volga Federal District, and Denis Manturov, Minister of Industry and Trade of the Russian Federation, took part in the ceremonial launch of the production and packaging line of solid medicines at the Nanolek LLC enterprise in the Kirov Region. Together with the Governor of the Kirov region Nikita Belykh, they launched the first stage of the biopharmaceutical complex. Before the start of the ceremony, Mikhail Babich and Denis Manturov inspected the new production workshops of the enterprise.

The policy of import substitution is one of the main priorities identified by the Head of State. The new enterprise is an example that clearly demonstrates that the domestic industry is able to produce high-tech pharmaceutical products that can openly compete in the market with the best world samples.

Nanolek relies on the development of its own drugs, which are among the most complex and high-tech, in cooperation with leading Russian scientific institutions. And in two years it will be an enterprise where new technologies and products are being developed in one of the most promising segments – biopharmaceuticals. "In the near future, the company plans to launch 15 innovative drugs on the market, the development of which is supported by the state under the Pharma 2020 program," said Denis Manturov, Minister of Industry and Trade of the Russian Federation.

The implementation of this project on the territory of the Kirov biopharmaceutical cluster "Vyatka-Biopolis" will create by 2015 about 350 new jobs with decent wages (about 34 thousand rubles) and will provide a full cycle of production of medicines – from the creation of the substance to its mass production.

The project implementation period is 2011-2017. The total cost of the project is 4095.1 million rubles. The total volume of manufactured products by 2017 is more than 1.5 billion tablets, more than 35 million vials and 42 million syringes per year. In June 2015, the launch of the 2nd stage of the plant is planned. In 2016, it is planned to establish the production of antitumor drugs, such as lomustin and procarbazine, as well as a means for the treatment of leukemia. The release of an innovative influenza vaccine is planned for 2017.

For reference.

The main consumer in the market of medicines and medical products is the state. Public procurement accounts for a significant share – about 85 percent. But in their structure, only 26.6% is accounted for by domestic drugs.

The creation of such production facilities will allow us to solve the important task of replacing imported medicines with domestic drugs. According to statistics, the share of imports in the medical and pharmaceutical industry in monetary terms is about 70-80%.

At the moment, 6 investment projects are being implemented in the Volga Federal District in the field of medicine and healthcare, contributing to import substitution, export growth and technological development, the total volume of planned investments for which is 11 billion rubles. 4 more projects with a total planned investment of 2.9 billion rubles are being prepared for implementation.

In terms of the volume of production of medical devices and medicines, the Volga Federal District occupies one of the leading places among federal districts. The share of the regions of the district as a whole accounts for 23.2% of the total volume of production of medical devices and 24.3% of medicines.

According to the results of 10 months of the current year, medicines worth 35.7 billion rubles were produced in the district, which is 15.8% more than in the same period of 2013 (in Russia, the growth was 9.9%). The increase in production is mainly due to the increase in volumes and expansion of the line of drugs produced by the largest enterprises of the industry located in the district.

Medical devices are produced by all regions of the district, with the exception of the Orenburg region. The leaders are the Nizhny Novgorod Region (28.4% of the total production of medical devices in the district in value terms following the results of the 1st half of 2014) and the Republic of Tatarstan (25.6%).

The production of medicines is available in all regions except the Orenburg and Ulyanovsk regions. The leader in terms of production in value terms at the moment is the Republic of Bashkortostan (10.4% of the total production of medicines in the district in value terms).

Portal "Eternal youth" http://vechnayamolodost.ru24.12.2014